CRISPR Gene Scissors: Eradicating the Roots of Cancer-Causing Viruses
-
A precision weapon that excises the viral seeds of cancer A substantial proportion of cancers arising in the body originate from viral infections such as HPV (human papillomavirus) or HBV (hepatitis B virus). These viruses covertly integrate into the host genome and embed oncogenic blueprints that drive malignant transformation, and conventional therapies have struggled to eradicate such deeply rooted viral elements.
-
Cas9 and Cas13: Targeting both viral DNA and RNA The research team devised a strategy that employs Cas9 against DNA viruses and Cas13 against RNA viruses, precisely excising the viral genome. By blocking replication pathways or directly cleaving concealed viral genetic material, this approach aims to fundamentally halt the cellular progression toward malignancy.
-
Next‑generation anticancer strategy armed with precision Off‑target cleavage and delivery efficiency remain challenges. However, the combination of high‑performance gene‑editing variants and nanoparticle delivery platforms is progressively addressing these obstacles, thereby enhancing clinical translatability.
-
Future significance and outlook If translated into clinical practice, this technology could dramatically improve cure rates for virus‑driven cancers such as hepatocellular carcinoma and cervical cancer. Gene‑editing is poised to become a frontline defense in oncology, potentially liberating humanity from the persistent threat of oncogenic viral diseases.
CRISPR/Cas systems, initially characterized as bacterial adaptive immune mechanisms, have rapidly emerged as precise and versatile genome-editing tools with significant potential for antiviral research and therapeutic development. This review highlights the role of CRISPR/Cas systems in targeting persistent and human oncogenic viruses, including HPV, HBV, HCV, EBV, KSHV, HTLV-1, and MCPyV, as well as HIV, which may indirectly contribute to cancer through immune dysregulation. Many of these viruses can integrate into the host genome or persist as chronic or latent infections, contributing to cancers for which curative options are limited. CRISPR-based strategies enable the excision of integrated proviral DNA, disruption of viral replication, targeted silencing of viral transcripts, and modulation of host tumor-suppressor pathways. Cas9 efficiently targets DNA viruses, such as HBV and HPV, whereas RNA-targeting Cas13 allows precise silencing of RNA viruses, like HCV. Editing T-cell receptors, including CCR5 and CXCR4, offers the potential for long-term resistance to HIV. CRISPR-based preclinical studies indicate the potential to disrupt HBV cccDNA, suppress EBV and KSHV latency gene expression, and inactivate HTLV-1 oncogenes, thereby potentially reducing viral persistence and oncogenic progression. Despite these advances, challenges remain regarding off-target effects, delivery efficiency, immune responses, and ethical considerations. Innovations such as high-fidelity Cas variants, base and prime editing, and non-viral delivery systems are expected to enhance both safety and therapeutic precision. This review provides an overview of viral life cycles, oncogenic pathways, and therapeutic vulnerabilities of human oncogenic viruses and CRISPR-based genome-editing approaches under investigation for viral elimination and cancer therapy.
It overcomes the longstanding medical limitation of being unable to directly excise the entrenched viral roots that persist lifelong and drive cancer. By applying a single gene‑editing intervention, lethal diseases such as cervical cancer and hepatocellular carcinoma can be addressed, paving the way for a future free from cancer concerns.